Healiva is a biotech company focused on developing personalized and affordable end-to-end solutions for chronic wound care. Their portfolio includes an epidermal cell graft, an enzymatic debriding agent, an allogenic cell spray, and a point-of-care blood patch. These innovations aim to improve patient outcomes for hard-to-heal wounds by offering more effective and efficient treatment options.
Funding
$6.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Chronic and acute wounds, including venous/arterial leg ulcers and diabetic foot ulcers, affect a significant portion of the global population, leading to pain, disability, and high healthcare costs. Current treatment methods often involve repeated surgical procedures, frequent dressing changes, lengthy hospital stays, and require specialized medical expertise, resulting in inefficient and costly care. A large percentage of these wounds remain unhealed, creating a substantial unmet need for effective and affordable therapies.
Solution
Healiva is a biotech company focused on developing and commercializing personalized and affordable therapies for chronic and acute wound care. Their approach integrates cell therapies, enzyme technology, and medical devices to address key challenges in the patient care pathway. Healiva's portfolio includes Epidex, an epidermal cell graft for severe chronic wounds; AQUAtyrp, an enzymatic debriding agent for effective wound cleaning and preparation; Healiva 002, an allogenic cell spray for growth factor stimulation; and Healiva 004, a blood patch prepared at the point of care. These solutions aim to improve patient outcomes by accelerating healing, reducing the need for frequent interventions, and enabling patients to return to their normal routines.
Target Audience
Healiva's primary customers include hospitals, medical practitioners, and insurance providers seeking advanced and cost-effective solutions for wound management, as well as patients suffering from chronic and acute wounds.
Features
- Epidex: Personalized epidermal cell graft treatment for severe chronic wounds.
- AQUAtyrp (Healiva 003): Painless and easy-to-use enzymatic debriding agent for effective wound cleaning.
- Healiva 002: Allogenic cell spray for growth factor stimulation, scalable to a large number of patients.
- Healiva 004: Autologous blood patch prepared at the point of care by healthcare professionals.
- Multi-pronged approach combining cell therapies, enzyme technology, and medical devices for comprehensive wound care.